EGFR-TKIs在晚期EGFR受体突变肺鳞癌患者中的临床应用  

Clinical Efficacy of EGFR-TKIs for Advanced Squamous-cell Lung Cancer Patients with EGFR Mutations

作　　者：吴洪波[1] 李明智[1] 史亮[1] 陶虹[1] 唐俊舫[1] 刘喆[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤科,101149

出　　处：《结核病与胸部肿瘤》2017年第1期18-21,共4页Tuberculosis and Thoracic Tumor

摘　　要：目的探讨表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors，EGFR-TKIs）对具有表皮生长因子受体（epidermal growth factor receptor，EGFR）突变的晚期肺鳞癌患者临床疗效。方法回顾性分析首都医科大学附属北京胸科医院2010年1月至2016年7月收治的2317例肺鳞癌患者，筛选出有明确随访记录的7例确诊具有EGFR突变的肺鳞癌患者，使用EGFR．TKI如吉非替尼、厄洛替尼治疗，直至疾病进展（progressivedisease，PDo结果使用EGFR-TKI治疗后，患者客观缓解率（objective response rate，ORR）42．9％，疾病控制率（disease control rate，DCR）100％（7／7），中位无进展生存期6．1个月。结论EGFR-TKI对EGFR突变的肺鳞癌患者具有一定临床疗效。但本研究病例数少仅有7例，亟需更多的病例来进行补充研究及验证上述结论。Objective To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods We screened out seven patients who were diagnosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from 2,317 squamous-cell lung cancer patients treated at the Beijing Chest Hospital from January 2010 to July 2016. Results After using EGFR-TKIs, the objective response rate was 42.9%, the disease control rate was 100%, and the median progression-free survival was 6.1 months. Conclusion EGFR-TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous-cell lung cancer. However, only seven cases are presented in this research group, more cases are needed for further research to verify the above conclusion.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 肺鳞状细胞癌 基因突变 

分 类 号：R339.2[医药卫生—人体生理学]